Summit Therapeutics plc (‘Summit’ or the ‘Company’) Director Change Oxford, UK, and Cambridge, MA, US, 11 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, announces that Valerie Andrews, a Non-Executive Director, is stepping down from the board of the Company with effect from today. The Board...
Category: News
Half-year report
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended 31 July 2019 Reported Additional Positive Phase 2 Data Showing Ridinilazole Improved Quality of Life and Microbiome Preservation Compared to Standard of Care Appointed Key Marketing Hires Focused on Potential US Commercialisation for...
Notice of Results
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2019 on 11 October 2019 Oxford, UK, and Cambridge, MA, US, 10 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) a leader in new mechanism antibiotic innovation, will announce its...
SCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program
JERSEY CITY, N.J., Oct. 10, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, has received notification from the State of New Jersey of its available unused net operating losses (NOLs) and R&D tax credits that can be sold under the New Jersey Economic Development...
Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection Data Presented at ID Week 2019 Oxford, UK, and Cambridge, MA, US, 7 October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today...
Entasis Therapeutics Announces Multiple Presentations at ID Week 2019
WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced its participation in an industry panel presentation and delivery of two poster presentations demonstrating the antibacterial activity of lead candidate sulbactam-durlobactam at ID Week 2019, taking place October 2-6 at the Walter E....
Entasis Therapeutics Announces Multiple Presentations at ID Week 2019
CEO Dr. Manos Perros participated in Industry Panel today WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced its participation in an industry panel presentation and delivery of two poster presentations demonstrating the antibacterial activity...
CIDARA THERAPEUTICS TO PRESENT NEW CLINICAL AND PRECLINICAL DATA AT TWO UPCOMING MEDICAL CONFERENCES
SAN DIEGO, Oct. 03, 2019 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three posters at the Infectious Diseases Society of America (IDSA) IDWeek 2019, which takes place October 2-6, 2019, in Washington, D.C., and four posters, including a late-breaking poster,...
Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care Statistically Significant Improvements in Physical and Mental Health Measures Benefit of Ridinilazole Treatment Seen as Early as Day Five Data from Phase 2 Clinical...
Block Listing Six Month Review
BLOCK LISTING SIX MONTHLY RETURN (Note: Italicised terms have the same meaning as given in the Listing Rules.) Date: 3 October 2019 Name of applicant: Summit Therapeutics plc Name of scheme: 2005 EMI Scheme Period of return: From: 31 Mar 2019 To: 30 Sept 2019 Balance of unallotted securities under scheme(s) from previous return: 776,756...